Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Victoria

$21,000.00

Discovery and investigation of cell type abundance biomarkers using single-cell and bulk genomic data

FY 2022-23

Summary
The proposed research program will develop the first software pipeline to discover biomarkers based on cell type abundance (using single-cell genomics technology) and to validate their relevance to clinical outcomes (or other phenotypes) in large-scale genomic studies. Background: The tissue microenvironment consists of a dynamic mixture of various cell types. The changes in cell type abundance can modify an organ's conditions and functions. Hence, the biomarkers based on cell type abundance can be used as drug targets for various diseases. Our novel procedure of discovering and investigating the cell type abundance biomarkers involves three steps. In step 1, we use single-cell RNA-sequencing (scRNA-seq) to identify all cell types in a specific type of tissue and infer their abundance. The discovered biomarkers are the abundance of specific cell types that vary significantly between healthy and diseased persons. Although the new scRNA-seq technology enables us to study tissues at the single-cell level, statistical methods and software are urgently needed to extract information from the data and make inferences precise. Validating the abundance-biomarkers' clinical relevance requires many samples. Conducting such large-scale studies using scRNA-seq is not practical due to the limitations of single-cell technology. So, the step 2 is developing digital cytometry methods to bridge information between scRNA-seq and bulk RNA-seq, which enables the inference of cell type abundance by using more affordable bulk RNA-seq. At last, the step 3 is to conduct a large-scale genomic study and analyze the data to evaluate the biomarkers' clinical relevance. Objectives: My research objectives are motivated by supporting the three steps discussed above respectively. First, I will develop novel statistical methods and software to annotate cell types and infer their abundance using scRNA-seq data. Second, I will develop novel digital cytometry methods based on the scRNA-seq data. Third, I will develop novel statistical methods to support the design and analysis of large-scale genomic studies, including three research areas: the design of clinical trials, causal inference, and multitask predictions. I will conduct the proposal by training highly qualified personnel (HQP) under equity, diversity, and inclusion guidelines. Research deliverables and impacts: My primary deliverables are the statistical methods and the software pipeline, which other researchers can use in their genomic studies. Those methods will be applied to discover biomarkers based on the abundance of alveolar macrophages subtypes, which will be used as immunotherapy drug targets for chronic obstructive pulmonary disease (COPD). In Canada, COPD is the top 1 reason for hospitalization, which costs over $1.5 billion/yr in direct expenditures to treat two million COPD patients. No current therapy can reverse disease's progression of COPD. Our research may lead to the first therapy that cures COPD.
Program
Discovery Grants Program - Individual
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2022-03050
Name nom
Zhang, Xuekui
Department département
Mathematics and Statistics - Mathematics and Statistics
Organization id
7
Institution établissement
University of Victoria
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
21000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1508
Committee name en
Mathematics and Statistics
Committee name fr
Mathématiques et statistique
Area of application code
1101
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Human health (including medically-related psychological research)
Area of application fr
Santé publique (y compris recherche psychologique liée à la médecine)
Research subject code
3000
Research subject group en
Statistics and probability
Research subject group fr
Statistique et probabilité
Research subject en
Statistics and probability
Research subject fr
Statistique et probabilité
Installment
inst:1
Partie
1
Nb partie
5
Application title
Discovery and investigation of cell type abundance biomarkers using single-cell and bulk genomic data
Application summary
The proposed research program will develop the first software pipeline to discover biomarkers based on cell type abundance (using single-cell genomics technology) and to validate their relevance to clinical outcomes (or other phenotypes) in large-scale genomic studies. Background: The tissue microenvironment consists of a dynamic mixture of various cell types. The changes in cell type abundance can modify an organ's conditions and functions. Hence, the biomarkers based on cell type abundance can be used as drug targets for various diseases. Our novel procedure of discovering and investigating the cell type abundance biomarkers involves three steps. In step 1, we use single-cell RNA-sequencing (scRNA-seq) to identify all cell types in a specific type of tissue and infer their abundance. The discovered biomarkers are the abundance of specific cell types that vary significantly between healthy and diseased persons. Although the new scRNA-seq technology enables us to study tissues at the single-cell level, statistical methods and software are urgently needed to extract information from the data and make inferences precise. Validating the abundance-biomarkers' clinical relevance requires many samples. Conducting such large-scale studies using scRNA-seq is not practical due to the limitations of single-cell technology. So, the step 2 is developing digital cytometry methods to bridge information between scRNA-seq and bulk RNA-seq, which enables the inference of cell type abundance by using more affordable bulk RNA-seq. At last, the step 3 is to conduct a large-scale genomic study and analyze the data to evaluate the biomarkers' clinical relevance. Objectives: My research objectives are motivated by supporting the three steps discussed above respectively. First, I will develop novel statistical methods and software to annotate cell types and infer their abundance using scRNA-seq data. Second, I will develop novel digital cytometry methods based on the scRNA-seq data. Third, I will develop novel statistical methods to support the design and analysis of large-scale genomic studies, including three research areas: the design of clinical trials, causal inference, and multitask predictions. I will conduct the proposal by training highly qualified personnel (HQP) under equity, diversity, and inclusion guidelines. Research deliverables and impacts: My primary deliverables are the statistical methods and the software pipeline, which other researchers can use in their genomic studies. Those methods will be applied to discover biomarkers based on the abundance of alveolar macrophages subtypes, which will be used as immunotherapy drug targets for chronic obstructive pulmonary disease (COPD). In Canada, COPD is the top 1 reason for hospitalization, which costs over $1.5 billion/yr in direct expenditures to treat two million COPD patients. No current therapy can reverse disease's progression of COPD. Our research may lead to the first therapy that cures COPD.